Clindamycin

Class: Lincosamide

Spectrum of activity:	Gram-positive
Details of activity:	Binds to the rRNA of the bacterial 50S ribosome subunit, overlapping with the binding sites of the oxazolidinone, pleuromutilin, and macrolide antibiotics, thus blocking ribosomal translocation. Bacteriostatic activity against Gram-positive bacteria including many MRSA strains.
Description:	Semisynthetic lincosamide derived from lincomycin. Oral and parenteral application. Alternative treatment of protozoal diseases and anaerobic bacterial infections.
Year first mentioned:	1964
Development status:	Approved, off-patent

Chemical structure(s):
Canonical SMILES:	CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)N(C)C1
Isomeric SMILES:	CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
InChI:	InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
InChI Key:	KDLRVYVGXIQJDK-AWPVFWJPSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/446598

External links:
Guide to Pharmacology:	clindamycin
Main Source:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250868/
Citations:	https://pubmed.ncbi.nlm.nih.gov/33278179/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137603/